You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
X Demographics
Mendeley readers
Attention Score in Context
| Title |
Assessment of the Pharmacokinetics, Pharmacodynamics, and Safety of Single Doses of TV‐1106, a Long‐Acting Growth Hormone, in Healthy Japanese and Caucasian Subjects
|
|---|---|
| Published in |
Clinical Pharmacology in Drug Development, September 2016
|
| DOI | 10.1002/cpdd.294 |
| Pubmed ID | |
| Authors |
Orit Cohen‐Barak, Hadas Barkay, Michele Rasamoelisolo, Kathleen Butler, Kazumasa Yamada, Merav Bassan, Esther Yoon, Ofer Spiegelstein |
| Abstract |
TV-1106 is a human serum albumin genetically fused to recombinant human growth hormone, designed to provide a long-acting alternative to daily GH injections in patients with GH deficiency. This study investigated the pharmacokinetics, pharmacodynamics and safety of single subcutaneous doses of TV-1106 (7.5, 15, 50 and 100mg) in Japanese (n = 44) and Caucasian (n = 44) healthy subjects. TV-1106 pharmacokinetics and pharmacodynamics were comparable in Japanese and Caucasian populations. TV-1106 demonstrated relatively slow absorption (median tmax 10-30 hours) and mean elimination half-life of 26-36 hours. Apparent clearance and volume of distribution decreased with increasing TV-1106 doses in both populations and appeared to increase more than dose proportionality across the tested doses. Insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3) increased in a dose-related manner with maximum responses observed at 33-96 hours and 42-109 hours, respectively. IGF-1 and IGFBP-3 returned to baseline values at 168 hours following 7.5 and 15 mg TV-1106, and 336 hours following 50 and 100mg TV-1106. TV-1106 appeared safe in both populations. There was no evidence of differences in pharmacokinetics, pharmacodynamics or safety of TV-1106 between Japanese and Caucasian populations. The data also demonstrate long-acting growth hormone properties of TV-1106 and support its potential for once-weekly dosing. This article is protected by copyright. All rights reserved. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 16 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 16 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 3 | 19% |
| Student > Doctoral Student | 2 | 13% |
| Student > Ph. D. Student | 2 | 13% |
| Student > Postgraduate | 2 | 13% |
| Researcher | 2 | 13% |
| Other | 1 | 6% |
| Unknown | 4 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Pharmacology, Toxicology and Pharmaceutical Science | 3 | 19% |
| Biochemistry, Genetics and Molecular Biology | 3 | 19% |
| Nursing and Health Professions | 2 | 13% |
| Environmental Science | 1 | 6% |
| Chemical Engineering | 1 | 6% |
| Other | 3 | 19% |
| Unknown | 3 | 19% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 January 2021.
All research outputs
#7,474,737
of 24,577,646 outputs
Outputs from Clinical Pharmacology in Drug Development
#86
of 377 outputs
Outputs of similar age
#106,292
of 326,712 outputs
Outputs of similar age from Clinical Pharmacology in Drug Development
#5
of 15 outputs
Altmetric has tracked 24,577,646 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 377 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.7. This one has done well, scoring higher than 76% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 326,712 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 15 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.